ArticleMolecular biology reports2026
Effect of irisin on miRNA-associated changes in the PGC-1α/FNDC5/BDNF Axis in an in vitro model of MPP⁺-induced Parkinson's disease.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIn this study, the neuroprotective potential of irisin was evaluated in an MPP⁺-induced SH-SY5Y in vitro Parkinson’s disease model through miRNA-associated changes related to the PGC-1α/FNDC5/BDNF axis. MATERIAL AND
methodAn in vitro Parkinson’s disease model was established by treating SH-SY5Y cells with 1500 μM MPP⁺ for 24 h. A non-cytotoxic irisin concentration (20 nM) was determined via using the MTT assay. Cells were divided into control, MPP⁺, irisin pre-treatment, and post-treatment groups. miRNA and mRNA expression levels were quantified by qRT-PCR and analyzed using the 2⁻ΔΔCt method.
resultsFNDC5 and BDNF levels were significantly decreased in the MPP⁺ group compared with the control group (p < 0.05). Conversely, PGC-1α expression was significantly increased in both the irisin pre- and post-treatment groups. Compared with the MPP⁺ group, PGC-1α expression was significantly elevated under both treatment conditions, while FNDC5 expression showed a significant increase, particularly in the pre-treatment group. miRNA analysis revealed a significant downregulation of miR-129-1-3p and miR-143-3p in the MPP⁺ group compared to the control. Irisin pre-treatment significantly increased miR-143-3p and miR-182-5p levels, whereas post-treatment significantly elevated miR-129-1-3p, miR-138-5p, and miR-182-5p expression, compared with the control group. Compared with the MPP⁺ group, miR-129-1-3p and miR-182-5p were upregulated in both treatment groups; whereas miR-143-3p increased predominantly in the pre-treatment group, and miR-138-5p showed a significant increase only in the post-treatment condition.
conclusionThese findings demonstrate that irisin influences the PGC-1α/FNDC5/BDNF axis and selected miRNAs in an MPP⁺-induced in vitro Parkinson's disease model. The observed results indicate an association between irisin treatment and miRNA expression changes rather than a direct miRNA-mediated regulatory mechanism. Further functional studies are required to establish causal relationships and validate the predicted miRNA–target interactions.
Indexed as
Identifiers
42053899What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.